Article

B + L recalls dry eye drop

Bausch + Lomb (B+L) has voluntarily recalled one lot of a 1% methylcellulose lubricant ophthalmic solution (Murocel) after routine stability testing showed that its preservative was ?out of specification? for efficacy.

Madison, NJ-Bausch + Lomb (B + L) has voluntarily recalled one lot of a 1% methylcellulose lubricant ophthalmic solution (Murocel) after routine stability testing showed that its preservative was “out of specification” for efficacy.

No adverse events attributed to the issue have been reported, the company said, adding that potential adverse events could include eye pain, change in vision, redness or irritation of the eye, or ocular infection.

The over-the-counter eye drop has been available for more than a decade for the temporary relief of burning and irritation due to dry eye. It is sold only in the United States.

B + L has informed eye-care professionals of the recall and has told U.S. retailers how they can return the product. Consumers who have purchased the recalled eye drop should return it to B + L; they may call 800/553-5340 for instructions on how to do so and obtain reimbursement. The customer service line is available weekdays from 9 a.m. to 5 p.m. Eastern Time.

Details about the recalled solution:

Lot number: 507521
Expiration date: Jan. 31, 2012
UPC code: 3 24208 28015 7
Case code: (01)50324208280154(30)00144

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.